Serum adiponectin in relation to endometrial cancer and endometrial hyperplasia with atypia in obese women

Objectives: The aim of this work was to compare concentrations of adiponectin in the serum of obese women with endometrial cancer, endometrial hyperplasia with atypia. and normal endometrium. Methods: We enrolled 105 obese women treated at the Department of Gynecological Surgery and Oncology of Adults and Adolescents. The patients were allocated to groups depending oil the histological diagnosis (R - endometrial cancer, P - polyps. K - normal endometrium). We subdivided group R depending oil the stage and grade of cancer. Results: Significantly lower concentrations of adiponectin were found in patients with endometrial cancer (mean 15.28 mu g/ml) as compared with polyps (29.94 mu g/ml, p < 0.001) or normal endometrium (22.7 mu g/ml, p < 0.05). Stage of cancer had no significant effect oil the adiponectin level. When cancer grade was compared, lower levels of adiponectin were observed in patients with G3 (12.86 mu g/ml) than G1 (19.04 mu g/ml, p < 0.05). Conclusion: Reduced levels of adiponectin may represent all independent risk factor for endometrial cancer

Endometrial cancer; Endometrial hyperplasia; Adiponectine; Obesity

[1] Fruhbeck G., Gomez-Ambrozi J., Muruzaba F.J., Burrel M.A.: “The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation”. Am. J. Physiol. Endocrinol. Metabol., 2001, 280, E827.

[2] Gannage-Yared M.H., Khalife S., Semaan M., Fares F., Jambart S., Halaby G.: “Serum adiponectin and leptin levels in relation to the metabolic syndrome, androgenic profile and somatotropic axis in healthy non-diabetic elderly men”. Eur. J. Endocrinol., 2006, 155, 167.

[3] Tataranni P.A., Ortega E.: “A burning question: does an adipokineinduced activation of the immune system mediate the effect of the overnutrition on type 2 diabetes”? Diabetes, 2005, 54, 917.

[4] Kelesidis I., Kelesidis T., Mantzoros C.S.: “Adiponectin and cancer: a systematic review”. Br. J. Cancer, 2006, 94, 1221.

[5] Lara-Castro C., Fu Y., Chung B.H., Garvey W.T.: “Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease”. Curr. Op. Lipidol., 2007, 18, 263.

[6] Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E.: “Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia”. J . Clin. Endocrinol. Metabol., 2001, 86, 1930.

[7] Cong L., Gasser J., Zhao J., Yang B., Li F., Zhao A.Z.: “ Human adiponectine inhibits cell growth and induces apoptosis in human endometrial carcinoma cells, HEC-1-A and RL 952”. Endocr. Relat. Cancer, 2007, 14, 713.

[8] Vona-Davis L., Rose D.P.: “Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression”. Endocr. Relat. Cancer, 2007, 14, 189.

[9] Chow W.S., Cheung B.M., Tso A.W., Xu A., Wat N.M., Fong C.H. et al.: “Hypoadiponectinemia as a predictor for the development of hypertension. A 5-year prospective study”. Hypertension, 2007, 49, 1455.

[10] Brooks N.L., Moore K.S., Clark R.D., Perfetti M.T., Trent C.M., Combs T.P.: “Do low levels of circulating adiponectin represent a biomarker or just another risk factor for the metabolic syndrome?”. Diabet. Obstet. Metabol., 2007, 9, 246.

[11] Ouchi N., Shibata R., Walsh K.: “Targeting adiponectin for cardioprotection”. Exp. Opin. Ther. Targets, 2006, 10, 573.

[12] Trujillo M.E., Scherer P.E.: “Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome”. J. Int. Med., 2005, 257, 167.

[13] Modan-Moses D., Stein D., Pariente C., Yaroslavsky A., Ram A., Faigin M. et al.: “Modulation of adiponectin and leptin during refeeding of female anorexia nervosa patients”. J. Clin. Endocrinol. Metabol., 2007, 92, 1843.

[14] Nagamani M., Stuart C.A.: “Specific binding and growth-promoting activity of insulin in endometrial cancer cells in culture”. Am. J. Obstet. Gynecol., 1998, 179, 6.

[15] Korner A., Kratzsch J., Gausche R., Schaab M., Erbs S., Kiess W.: “New predictors of the metabolic syndrome in children - role of adipocytokines”. Pediatr. Res., 2007, 61, 640.

[16] Soliman P.T., Wu D., Tortolero-Luna G., Schmeler K.M.: “Association between adiponectin, insulin resistance, and endometrial cancer”. Cancer, 2006, 106, 2376.

[17] Cust A.E., Kaaks R., Friedenreich C., Bonnet F., Laville M., Lukanova A. et al.: “Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women”. J. Clin. Endocrinol. Metabol., 2007, 92, 255.

[18] Dal Maso L., Augustin L.S., Karalis A.: “Circulating adiponectin and endometrial cancer risk”. J. Clin. Endocrinol. Metabol., 2004, 89, 1160-3.

[19] Petridou E., Mantzoros C., Dessypris N.: “Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece”. J. Clin. Endocrinol. Metabol., 2003, 88, 993.

[20] Takemura Y., Osuga Y., Yamauchi T.: “Expression of adiponectin receptors and its possible implication in the human endometrium”. Endocrinol., 2006, 147, 3203.

[21] Fu Y., Luo N., Klein R.L., Garvey W.T.: “Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation”. J. Lipidol. Res., 2005, 46, 1369.

[22] Lihn A.S., Pedersen S.B., Richelsen B.: “Adiponectin: action, regulation and association to insulin sensitivity”. Obstet. Rev., 2005, 6, 3.